Characterizing Ohio River NOM Variability and Reconstituted-Lyophilized NOM as a Source Surrogate.

Natural organic matter (NOM) was collected, concentrated, and lyophilized on a monthly basis for 15 months to create a temporal NOM library and assess seasonal variability of untreated Ohio River water. Using fluorescence spectroscopy with parallel factor analysis, similar spectral components for both the ultrafiltered source water (UF1X) and reconstituted lyophilized NOM were observed in a two-component model throughout the study, with overall average emission and excitation wavelengths of 418 nm and 270 nm, respectively, for component 1 and 482 nm and 370 nm, respectively, for component 2. Fluorescence spectroscopy, high-pressure liquid chromatography-size exclusion chromatography, and elemental analysis indicated that the NOM was humic-like during the study with only small seasonal changes. Data from these analyses also demonstrated similarity between results for UF1X, reverse osmosis-concentrated NOM, and reconstituted- lyophilized NOM, validating the use of the reconstituted- lyophilized NOM as a surrogate for its source.

Evaluation of Preformed Monochloramine Reactivity with Processed Natural Organic Matter and Scaling Methodology Development for Concentrated Waters.

To evaluate natural organic matter (NOM) processing impacts on preformed monochloramine (PM) reactivity and as a first step in creating concentrated disinfection byproduct (DBP) mixtures from PM, a rational methodology was developed to proportionally scale PM NOM-related demand in unconcentrated source waters to waters with concentrated NOM. Multiple NOM preparations were evaluated, including a liquid concentrate and reconstituted lyophilized solid material. Published kinetic models were evaluated and used to develop a focused reaction scheme (FRS) that was relatively simple to implement and focused on monochloramine loss, including considerations for inorganic chloramine stability (i.e., autodecomposition) and bromide and iodide impacts. The FRS included critical reaction pathways and accurately simulated (without modification) monochloramine experimental data with and without bromide and iodide present over a range of PM-dosed NOM-free waters. For NOM-containing waters, addition of two NOM reactions in the FRS allowed (i) apportioning monochloramine loss to either inorganic or NOM-related reactions and (ii) selecting experiment conditions to provide an equivalent monochloramine NOM-related demand in unconcentrated and concentrated waters. The methodology provides a framework for future experimentation to evaluate DBP scaling and their speciation in concentrated water matrices when providing an equivalent NOM-related monochloramine demand in unconcentrated and concentrated matrices.

Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF-mutated Urothelial Carcinoma.

BRAF-targeted therapies including vemurafenib (Zelboraf) induce dramatic cancer remission; however, drug resistance commonly emerges. The purpose was to characterize a naturally occurring canine cancer model harboring complex features of human cancer, to complement experimental models to improve BRAF-targeted therapy. A phase I/II clinical trial of vemurafenib was performed in pet dogs with naturally occurring invasive urothelial carcinoma (InvUC) harboring the canine homologue of human BRAF V600E The safety, MTD, pharmacokinetics, and antitumor activity were determined. Changes in signaling and immune gene expression were assessed by RNA sequencing and phosphoproteomic analyses of cystoscopic biopsies obtained before and during treatment, and at progression. The vemurafenib MTD was 37.5 mg/kg twice daily. Anorexia was the most common adverse event. At the MTD, partial remission occurred in 9 of 24 dogs (38%), with a median progression-free interval of 181 days (range, 53-608 days). In 18% of the dogs, new cutaneous squamous cell carcinoma and papillomas occurred, a known pharmacodynamic effect of vemurafenib in humans. Upregulation of genes in the classical and alternative MAPK-related pathways occurred in subsets of dogs at cancer progression. The most consistent transcriptomic changes were the increase in patterns of T lymphocyte infiltration during the first month of vemurafenib, and of immune failure accompanying cancer progression. In conclusion, the safety, antitumor activity, and cutaneous pharmacodynamic effects of vemurafenib, and the development of drug resistance in dogs closely mimic those reported in humans. This suggests BRAF-mutated canine InvUC offers an important complementary animal model to improve BRAF-targeted therapies in humans.

Myositis, Ganglioneuritis, and Myocarditis with Distinct Perifascicular Muscle Atrophy in a 2-Year-Old Male Boxer.

A 2-year-old male, intact Boxer was referred for chronic diarrhea, hyporexia, labored breathing, weakness and elevated creatine kinase, and alanine aminotransferase activities. Initial examination and diagnostics revealed a peripheral nervous system neurolocalization, atrial premature complexes, and generalized megaesophagus. Progressive worsening of the dog's condition was noted after 36 h; the dog developed aspiration pneumonia, was febrile and oxygen dependent. The owners elected humane euthanasia. Immediately postmortem biopsies of the left cranial tibial and triceps muscles and the left peroneal nerve were obtained. Postmortem histology revealed concurrent myositis, myocarditis, endocarditis, and ganglioneuritis. Mixed mononuclear cell infiltrations and a distinct perifascicular pattern of muscle fiber atrophy was present in both muscles. This is a novel case of diffuse inflammatory myopathy with a distinct perifascicular pattern of atrophy in addition to endocarditis, myocarditis, and epicarditis.